@article{3119118,
    title = "Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis",
    author = "Rizos, E.D. and Antonogiannaki, E.-M. and Chatzidakis, A. and Kallieri, M. and Tsilogianni, Z. and Manali, E.D. and Economopoulos, N. and Triantafyllou, K. and Papiris, S.A. and Polymeros, D.",
    journal = "European Journal of Gastroenterology and Hepatology",
    year = "2021",
    volume = "33",
    number = "1S Suppl 1",
    pages = "e1057-e1059",
    publisher = "NLM (Medline)",
    issn = "0954-691X, 1473-5687",
    doi = "10.1097/MEG.0000000000002197",
    abstract = "Vedolizumab, an anti-integrin antibody, is effective for moderate to severe ulcerative colitis and Crohn's disease treatment with a good safety profile due to its gut selective mechanism of action. Upper respiratory tract vedolizumab adverse events are common; however, they are mild and do not require treatment withdrawal. Herein, we present a 39-year-old patient under vedolizumab treatment for ulcerative colitis who presented acute severe interstitial lung injury that necessitated vedolizumab withdrawal and systemic steroids administration. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved."
}